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Summary
The antineutrophil cytoplasmic antibody (ANCA) associ-
ated vasculitides (AAV) are a group of primary vasculitides
that affect predominantly small- to medium-sized blood
vessels. AAV include granulomatosis with polyangiitis
(GPA), microscopic polyangiitis (MPA) and eosinophilic
granulomatosis with polyangiitis (EGPA). Disease severity
is dictated by the location and extent of the blood vessels
affected. If left untreated, systemic forms of AAV are often
fatal. The advent of immunosuppressive therapy (cyclo-
phosphamide plus glucocorticoids) has revolutionised the
prognosis for patients with AAV, transforming the course
of the disease from fatal to one that can be managed,
though not without significant treatment-related toxicity.
Recently, the monoclonal antibody rituximab was ap-
proved for the treatment of GPA and MPA, providing the
first major alternative to cyclophosphamide for induction
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therapy of AAV. This review explores the emerging role of
rituximab in the management of this complex disorder.
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Introduction
The antineutrophil cytoplasmic antibody (ANCA) associ-
ated vasculitides (AAV) are chronic, relapsing, primary
vasculitides characterised by leucocyte infiltration of blood
vessel walls, fibrinoid necrosis and vascular damage [1].
Three heterogeneous syndromes fall under the term AAV:
granulomatosis with polyangiitis (GPA, formerly Wegen-
er’s granulomatosis), microscopic polyangiitis (MPA) and
eosinophilic granulomatosis with polyangiitis (EGPA,
formerly Churg-Strauss syndrome) [2]. In addition, AAV
can present as single-organ vasculitis, e.g. renal-limited
AAV. A hallmark of these disorders is the presence of cir-
culating antibodies to neutrophil cytoplasmic antigens, spe-
cifically, proteinase 3 (PR3) and myeloperoxidase (MPO)
[1]; hence they are called ANCA-associated vasculitides.
Granulomatous lesions in the upper and lower respiratory
tract often precede the appearance of symptoms in other or-
gans, a feature which distinguishes GPA from MPA [3].
When first described, severe systemic forms of these dis-
orders were mostly fatal. In the absence of treatment, the
mean survival for patients with systemic GPA was 5
months, and the 1-year mortality rate was 82% [4]. The
combination of cyclophosphamide (CYC) and glucocortic-
oids heralded a landmark in the management of AAV, trans-
forming this fatal disease into one that could be managed,
though not entirely cured [5, 6]. Despite this improvement,
however, a proportion of patients either do not respond to
CYC, or relapse after initial treatment [7]. Another major
obstacle in the management of AAV is the substantial tox-
icity associated with the repeated use of CYC, which in-
cludes infertility, cytopenia, infections, or malignancies.
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Indeed, these significant treatment-related adverse effects
have now moved to the forefront as more patients have last-
ing remissions with CYC. This underscores the need for
less toxic treatment modalities.
Rituximab (RTX) is a monoclonal anti-CD20 antibody that
selectively targets B cells. RTX is an established treatment
for rheumatoid arthritis and B cell lymphomas. RTX in
combination with glucocorticoids was recently approved
by the US Food and Drug Administration (FDA) for the
induction treatment of GPA and MPA. Amongst the
European countries, Switzerland led the way in approving
the use of RTX in combination with glucocorticoids for
the treatment of these diseases. Rather than a comprehens-
ive literature overview, our objective with this review is to
place RTX in the context of the current therapies used for
AAV. As such, this review will be organised around several
key questions relevant to the physicians who manage this
challenging disease.
Pathogenesis, clinical presentation
and standard therapy: how does
rituximab act in the pathogenesis of
AAV?
ANCAs are assumed to be important in the pathogenesis
of AAV. In mouse models, ANCAs have been shown to in-
duce glomerulonephritis [8]. The interaction of ANCA and
MPO or PR3 on the surface of neutrophils may result in
the activation and degranulation of neutrophils and mono-
cytes within capillaries, leading to inflammation and de-
struction of vascular endothelium [9–11]. In addition, the
number of activated B cells is associated not only with dis-
ease activity, but also correlates with the severity of dis-
ease symptoms [12] and autoantigen-specific B cells have
been identified at sites of inflammation [11, 13, 14]. Col-
lectively, these data provided a strong rationale for the use
of a B cell-depleting agent such as RTX in AAV [15]. Im-
portantly, there are also data on the presence of ANCA-
specific T cells and the complement pathway also plays an
important role in the initiation of vessel inflammation (re-
viewed in [16]).
RTX is a chimeric IgG1 antibody that binds to CD20 ex-
pressed exclusively on all cells of the B cell lineage except
the very early B cell precursors and the plasma cells [17,
18]. B cell depletion from peripheral blood, spleen and
lymph nodes is achieved by antibody-dependent cellular
cytotoxicity (ADCC), complement-dependent toxicity
(CDC) and apoptosis. However, the relevance of the differ-
ent pathways remains a matter of debate [18]. The early B
cell progenitor ‘sparing effect’ ensures repletion of B cells
after treatment. Plasma cells are not depleted and thus es-
tablished protective immune responses are not affected by
RTX treatment.
Treatment of AAV
Today, standard therapy consists of high-dose glucocortic-
oids plus intravenous or oral CYC over a period of 3–6
months for induction of remission [19]. Plasma exchange
has also been used to treat cases characterised by alveolar
haemorrhage and acute renal insufficiency [20]. With these
treatments, remission rates are between 30–93% in GPA
and 75–89% in MPA [19].
Once remission is achieved, this treatment is usually fol-
lowed by maintenance therapy, since AAV are chronic dis-
eases with a high risk of relapse. The use of azathioprine or
methotrexate has replaced CYC in remission maintenance
[21, 22]. Despite current maintenance treatments, around
50% of responders still relapse within 3–5 years and the
1–year mortality remains at around 12–18% [23]. Further-
more, around 20% of survivors develop end-stage renal
disease, adding to the clinical burden, which already in-
cludes increased incidence of cardiovascular disease, infec-
tions and malignancies [24]. The latter two are associated
with the use of immune suppressive agents, e.g. CYC and
glucocorticoids. Hence, a major focus has been to develop
novel therapeutic strategies that reduce toxicity while re-
taining efficacy.
What is the role of rituximab for remission induction
in AAV?
The earliest clinical evidence supporting the use of RTX
came from a case study in which a 66-year old man with
GPA, who relapsed despite treatment with azathioprine and
mycophenolate mofetil, and developed severe CYC-in-
duced bone marrow toxicity was treated with a combina-
tion of glucocorticoids plus RTX [25]. After four weekly
doses of 375 mg/m2 RTX, he experienced clinical remis-
sion, allowing discontinuation of glucocorticoids. RTX
alone was later used to treat another relapse in the same pa-
tient, thus introducing a new line of treatment for AAV.
Data for RTX in the induction therapy of patients with
newly-diagnosed AAV comes from two pivotal trials,
RAVE (rituximab for ANCA-associated vasculitis) [26–28]
and RITUXVAS (rituximab versus cyclophosphamide in
ANCA-associated vasculitis) [29]. Both trials were de-
signed to compare the efficacy and safety of RTX versus
CYC in the treatment of AAV.
RITUXVAS was an open-label study in which 44 patients
with newly-diagnosed ANCA-associated glomeruloneph-
ritis were randomised in a 3:1 ratio to receive either RTX
(375 mg/m2 per week for 4 weeks) or intravenous CYC
(3–6 months), followed by azathioprine for maintenance
of remission in the CYC group [29]. It is important to
note that patients in the RTX group also received intra-
venous CYC (15 mg/kg) along with the first and third
RTX infusions; those who had progressive disease within
the first 6 months were given an additional third dose of
CYC. The RTX group did not receive maintenance aza-
thioprine. The RTX arm achieved similar results to the
CYC cohort, with respect to complete remission (82% in
the RTX arm versus 91% in the CYC-only controls; p =
0.68). At the 2-year follow-up, relapse had occurred in
21% of the RTX arm (who had not received maintenance
therapy) as compared with 18% in the control group who
had received azathioprine maintenance treatment; p = 1.00
[30]). It is important to note, however, that the RITUXVAS
trial was underpowered to detect clinically relevant differ-
ences between the two treatments.
The RAVE trial differed from RITUXVAS in several im-
portant points, including in the study treatment protocol,
where RTX without the addition of CYC was compared
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directly to CYC. This multicentre, double-blind, placebo-
controlled trial included 197 patients with severe GPA and
MPA who were randomised to receive treatment with RTX
(375 mg/m2 per week for 4 weeks) or daily oral CYC
(2 mg/kg) for 3–6 months [26]. All patients in the CYC
group received a further 12–15 months’ treatment with aza-
thioprine. Another relevant distinction between RAVE and
RITUXVAS is the clinical profile of the patients. Only
half of the RAVE patients had glomerulonephritis and the
mean GFR was above 50 ml/min/1.73 m2 (vs all patients in
RITUXVAS, with mean GFR of 18 ml/min/1.73 m2); pa-
tients with serum creatinine levels >4 mg/dl were excluded
from the study and half of the patients had relapsing dis-
ease. Results from RAVE showed that RTX was non-inferi-
or to CYC for achieving glucocorticoid-free remission at 6
months (64% vs 53%; p = 0.09). Subgroup analysis indic-
ated that RTX appeared to be equally effective in those pa-
tients with glomerulonephritis or pulmonary haemorrhage
and that RTX induced a higher rate of remission than CYC
amongst patients with relapsing disease. Longer follow-up
(18 months) of the RAVE cohort confirmed that the initial
single course of RTX was as effective as CYC induction
plus azathioprine maintenance [31, 32].
Thus, the findings from both trials demonstrate that RTX
has an efficacy in remission induction comparable to that
of CYC and is likely superior in relapsing patients.
What maintenance immunosuppression to choose after
remission induction with RTX?
It is noteworthy that in both RAVE and RITUXVAS, those
patients in the RTX arms had similar long-term relapse
rates compared with those in the CYC arms, despite the
fact that they did not receive maintenance immunosup-
pressive agents. Therefore, it could be concluded that
maintenance immunosuppression is not required after RTX
treatment. However, the relapse rates in both the RAVE
and the RITUXVAS studies remained considerable. During
the 12-month follow-up period in RITUXVAS, 15% of pa-
tients in the RTX group versus 10% of those in the CYC
group had a relapse (non-significant; p = 0.70) [29]. In
RAVE, 32% of patients in the RTX arm versus 29% in
the CYC-azathioprine arm had a relapse between month 6
and month 18 [27]. A subgroup analysis of the RAVE tri-
al confirmed several previously known, strong risk factors
for relapse: relapsing disease (vs newly diagnosed) and
PR3–ANCA positivity (vs MPO-ANCA) [27]. Thus, main-
tenance immunosuppression with either azathioprine or re-
peated courses of RTX should be considered at least in
high-risk patients.
RTX for maintenance of remission
Apart from its use for remission induction, RTX has been
tested as an alternative to azathioprine for maintenance
treatment.
Several independent nonrandomised studies tested the op-
tion of pre-emptive RTX treatment to maintain remission
[33–39]. Multiple courses of RTX have been shown to in-
duce additional remissions after relapse, and pre-emptive
RTX retreatment can result in sustained remissions [33,
34]. In the 2-year follow-up of a study comparing
6-monthly, pre-emptive protocolised retreatment with RTX
(2 x 1g followed by 1 x 1g every 6 months for 2 years)
against nonprotocolised retreatment according to clinical
need (either 2 x 1g or 4 x 375 mg/m2 only upon relapse),
Jones et al. demonstrated that at 2 years relapse occurred
in 11 of 49 (22%) protocol patients versus 24 of 34 (71%)
nonprotocol patients (p <0.01) [34] and at the 44-month
follow-up, relapses had occurred in 22 of 26 (85%) of no-
protocol patients compared with 11 of 43 (26%) of those
who received pre-emptive RTX treatment (p <0.001) [39].
Glucocorticoid dosages were decreased and immunosup-
pressive therapy was withdrawn in the majority of patients.
These results have been supported by other studies [35, 36,
40], including a recent one that examined the feasibility
of continuous B cell depletion via administration of one
RTX dose every 4 months [37]. This regimen not only res-
ulted in a low relapse rate (average follow-up 28 months;
9 of 72 patients, 13%), but also allowed most patients to
be weaned off additional immunosuppressive medications
[37]. Very recently, the results of MAINRITSAN (main-
tenance using RTX in remission after vasculitis), the first
randomised controlled trial that evaluated RTX for main-
tenance treatment of AAV, have been published. In this
study, 115 patients (mainly with GPA) were randomised to
receive either azathioprine or RTX after remission induc-
tion with CYC and steroids. RTX was given at a reduced
dose of 500 mg on days 1 and 15 followed by repeat doses
of 500 mg after 6, 12 and 18 months. At month 28, ma-
jor relapses had occurred in 29% of patients in the aza-
thioprine group compared with only 5% of the RTX group
(p = 0.002) [41]. The rate of adverse events was similar.
The ongoing RITAZAREM study (RTX vasculitis main-
tenance study) is testing the efficacy of RTX at a higher
dose (1,000 mg every 4 months) in relapsing patients after
remission induction with RTX.
In summary, current data support the use of RTX to main-
tain remission in patients at high risk of relapse or in pa-
tients who have experienced multiple relapses, or relapses
while on alternative maintenance regimens. The optimal
dosing schedule, however, remains to be determined. It is
also unknown whether retreatment following a fixed sched-
ule is superior to treatment upon reconstitution of CD19+
cells or rise of ANCA titre. This question will be addressed
by the ongoing MAINRITSAN II study (NCT01731561).
In the RAVE study, relapses were only seen after B cell re-
covery in peripheral blood, whereas the rise in ANCA titre
was not predictive of relapse in these patients [27].
The characteristics and results of the randomised trials on
RTX in AAV are summarized in table 1.
The role of RTX in AAV patient subgroups
Refractory/relapsing disease
Despite aggressive induction regimens and maintenance
therapy, AAV is still plagued by a high rate of relapses,
with reported relapse rates ranging from 20% up to 50%
after 2 years [42]. Relapsing patients pose a special chal-
lenge to the physician, who has to manage symptoms of re-
current disease alongside the accrual of organ damage and
the side effects of prolonged CYC and steroid exposure
[43]. Although refractory and relapsing disease are often
treated in the same context, it is important to note the dis-
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tinction between refractory and relapsing disease. Disease
relapses occur after achieving remission with induction
therapy, whereas refractory disease does not actually re-
spond to initial therapy [44].
The bulk of supporting evidence comes from case series
and individual studies published over the last decade,
mainly in patients with GPA [3, 15]. More recent reports
further support the feasibility of RTX as rescue therapy in
patients with MPA and GPA, including in those with re-
fractory renal and ocular manifestations [45–49]. Results
from a prespecified subgroup analysis in the RAVE trial fa-
voured RTX plus prednisolone over standard CYC therapy
for patients with relapsing disease (6-month remission rates
67% vs 42%, respectively; p = 0.01). The superiority of
RTX-prednisolone in this patient subgroup persisted even
after adjusting for differences in ANCA type and clinical
site (odds ratio 1.40; 95% confidence interval 1.03–1.91; p
= 0.03) [26].
Taken together, and despite the heterogeneity of the treat-
ment regimens and patient populations in the studies so
far, RTX treatment has yielded consistently positive results
[50]. Indeed, the patient heterogeneity, varying disease
statuses and often severe comorbidities seen in the subset
of patients with refractory disease reflects the diverse clin-
ical spectrum routinely encountered in a real-life setting.
However, it must be kept in mind that many of the studies
used other immunosuppressive agents along with RTX, in-
cluding glucocorticoids.
Refractory granulomatous disease
Granulomatous disease in GPA is mostly localised and
manifests in the upper and lower airways [19]. Localised
GPA can also present in the form of inflammation restricted
to the eye [51]. The potentially destructive nature of loc-
alised GPA should not be underestimated [43]; moreover,
these manifestations are often resistant to treatment.
Indeed, patients with refractory disease are most often
those who suffer from granulomatous disease.
Individual case reports have shown that RTX treatment can
achieve clinical remission in GPA patients with pachymen-
ingitis, a rare manifestation of GPA [52, 53]. There is some
evidence that RTX may be used to treat orbital involve-
ment, although this matter is still under discussion [46,
54–56]. Case series in patients with refractory ophthalmic
GPA have reported that RTX is effective at inducing remis-
sion [47, 48], with efficacy in both vasculitic and granu-
lomatous manifestations [47]. However one retrospective
single-centre study of more than 50 patients with refractory
GPA hints at a lower response rate with granulomatous
disease manifestations compared with vasculitic manifest-
ations, after RTX treatment [46]. The uncertainty associ-
ated with RTX treatment of localised disease emphasises
the need to have more data before recommending the use
of RTX as an alternative to CYC.
Severe renal impairment
The presence of symptoms and laboratory features indicat-
ing kidney inflammation not only dictates an unfavourable
clinical course leading to end-stage renal disease if left un-
treated, it also diminishes the odds of survival [57]. Renal
involvement is present in around 70% of patients with GPA
and affects nearly all patients with MPA [57].
Both RAVE and RITUXVAS revealed that RTX was nonin-
ferior to CYC in patients with glomerulonephritis, defined
according to the inclusion criteria of the respective study
protocols. However, it must be noted that the RITUXVAS
study was underpowered to detect a clinically significant
difference between the two groups and included two intra-
venous CYC pulses, whereas in the RAVE trial, although
around half the patients had glomerulonephritis, those with
severe renal dysfunction (serum creatinine levels >4 mg/
dl, corresponding to 354 µmol/l) were excluded [26]. In the
West London Renal and Transplant Centre study, a non-
randomised prospective study, 23 patients with newly dia-
gnosed or relapsing renal AAV (excluding those with cre-
atinine levels >500 µmol/l or previous RTX treatment),
patients were treated with two pulses of 1 g RTX (2 weeks
apart) and 6 fortnightly doses of CYC (10 mg/kg body-
weight instead of 15mg/kg bodyweight as given in the
CYCLOPS trial [58]), followed by a sequentially reducing
protocol of daily prednisolone beginning with 20 mg and
azathioprine maintenance. All patients achieved prolonged
disease-free remission (median follow-up 39 months), with
three major and two minor relapses occurring in five pa-
tients at a median of 30 months [59]. However, the study
did not include a control group. Thus, firm data on the use
of RTX in patients with severe renal impairment (creatinine
>354 µmol/l) are lacking. For these patients, plasmapher-
esis followed by CYC has been shown to reduce the risk of
end-stage renal disease in the MEPEX trial [60]. However,
during longer follow-up the mortality in both groups was
high and did not differ significantly [61].
Whether plasmapheresis combined with RTX is effective
in patients with severe renal impairment has not yet been
shown. This approach may be feasible if plasmapheresis is
delayed for 24 hours after RTX, to ensure complete binding
of RTX to CD20.
RTX for eosinophilic granulomatosis with polyangiitis
(formerly Churg-Strauss syndrome, EGPA)
It should be emphasised that EGPA patients were excluded
from RAVE and RITUXVAS trials and results cannot be
extrapolated to this category of patients. Only few data are
available for the treatment of EGPA with RTX. Case re-
ports and small case series reported the efficacy of RTX in
refractory or relapsing patients with EGPA [62].
What is the optimal dosage for
rituximab when used as an induction
regimen?
According to the lymphoma protocol, RTX is administered
at a dose of 375 mg/m2/week for 4 weeks. The rheumatoid
arthritis protocol calls for two infusions of 1 g each, given
2 weeks apart, resulting in a lower total dose. The majority
of published studies, including the RAVE and RITUXVAS
trials, have employed the 4-dose lymphoma regimen for re-
mission induction [63]. In contrast, the 1 g fortnightly pro-
tocol has mainly been used to treat patients with refractory
disease [33, 54]. In an attempt to shed light on the optimal
dosing schedule, Jones et al. [33] compared these two regi-
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mens in a retrospective, multicentre study. Complete remis-
sion was achieved in 75% (57% of whom experienced an-
other relapse), and partial remission in 23% of patients; the
rate of remission was not related to the RTX regimen used.
Achieving sufficient RTX exposure may be important for
obtaining a clinical effect; a report citing the lack of effic-
acy used a less frequent dosing regimen [55], possibly res-
ulting in a lower cumulative exposure. In Switzerland, the
approved regimen for use in AAV is the four-dose sched-
ule (4 x 375 mg/m2 BSA/week), but due to the comparable
results obtained with the 2 x 1 g regimen, many clinicians
have adopted this dosing schedule for practical reasons. A
very recent trial used a single dose of 375 mg/m2 as in-
duction regimen in a small group of AAV patients. With-
in this heterogeneous population, B cell depletion could be
achieved in 90% of patients and the 3-month probability of
reaching a complete remission was 80% [64].
Safety of rituximab in patients with
AAV
Although the safety profile of RTX in lymphoma and
rheumatoid arthritis is well established, the situation in
AAV is less clear-cut. Recently, data on over 3,190 RTX-
treated rheumatoid arthritis patients who had received up to
17 courses of RTX over 9.5 years in the global clinical tri-
al programme were published [65]. This long-term safety
dataset revealed no evidence of an increased safety risk
or increased incidence of any adverse events with pro-
longed exposure to RTX, including no increased risk of
malignancy over this timeframe. In general, adverse effects
associated with RTX use include infusion reactions, hy-
pogammaglobulinaemia especially after repeated courses,
infections, reactivation of hepatitis B virus hepatitis and
late-onset neutropenia, which may manifest months after
therapy and is mostly asymptomatic and reversible [66]. In
patients with AAV, infections are a major cause of mor-
bidity and mortality, particularly during remission induc-
tion when the most intensive immunosuppressive regimens
are administered [67–69]. The use of systemic glucocortic-
oids as concomitant therapy with RTX or CYC enhances
immunosuppression. In many patients, B cell levels are de-
pleted for prolonged periods even after clinical recovery
[70]. Although its main action is depletion of B cells, RTX
has a significant impact on the immune and inflammatory
systems, and thus enhances susceptibility to infection [70].
Hypogammaglobulinaemia can be associated with devel-
opment of mostly bacterial infections [71, 72]. Interest-
ingly, data from the RAVE trial showed that the rates of
overall and serious infections at 18 months were similar
in patients who exhibited low immunoglobulin levels at
any point in time compared with those with normal im-
munoglobulin levels [73]. Another potential risk factor for
infections is late-onset neutropenia, an adverse effect that
is associated with RTX. Recent data from patients with
rheumatoid arthritis suggest that late onset neutropenia is
more prevalent than expected but is not associated with
neutropenic infections. However this has to be proven in
AAV [74, 75].
There have been reports on Pneumocystis jirovecii pneu-
monia in patients receiving RTX for autoimmune diseases
other than AAV [76]. Most of these cases had received pri-
or cytostatic therapy or RTX was paralleled by high doses
of steroids. Therefore PCP prophylaxis at least during in-
duction therapy with RTX for AAV should be considered.
Progressive multifocal leukoencephalopathy (PML) is a
rare demyelinating disorder of the brain caused by a ubi-
quitous polyomavirus, the JC virus. In a recently published
review Molloy and Calabrese [77] reported 34 confirmed
cases of PML in the setting of autoimmune rheumatic dis-
eases: 14 of these patients were under RTX; however none
of these patients had AAV.
There is an increased incidence of either previous or con-
current malignancies in patients with AAV [78], and the
risk of cancer augments with the use of conventional CYC-
based therapy [79, 80]. Malignancy is of special concern
when treating patients with severe glomerulonephritis. This
subset has often undergone heavy pretreatment, and the
risk of malignancy is a long-term safety issue. In the RAVE
and RITUXVAS trials, a similar incidence of malignancies
Table 1: Summary of results from randomised trials on rituximab in antineutrophil cytoplasmic antibody-associated vasculitis.
Study RAVE [26–28] RITUXVAS [29] MAINRITSAN [41]
Patient number (randomisation) 197 (1:1) 44 (3:1) 118 (1:1)
GPA / MPA / RL (%) 76/24/0 50/36/14 76/20/4
Renal involvement (%) 66 100 70
Newly diagnosed (%) 49 100 80
Treatment
Induction
(all plus PDN)
RTX 375 mg/m2 day 0, 7, 14 and 21
vs
p.o. CYC
RTX 375 mg/m2 day 0, 7, 14 and 21 + i.v.
CYC day 0 and 14
vs
IV CYC + PDN
i.v. CYC
(both groups)
Maintenance No maintenance (RTX group)
vs
azathioprine
No maintenance (RTX group)
vs
azathioprine
RTX 500 mg day 0, 14, month 6, 12 and
18
vs
azathioprine until month 22
Outcome Steroid-free remission in 64% (RTX) vs
53% (CYC-AZA) at month 6 and in 39%
vs 33% at month 18; RTX noninferior
RTX superior in relapsing disease p =
0.01
Sustained remission at month 12 in 76%
(RTX) vs 82% (CYC-AZA)
not significant
Major relapses at month 28 in 5% (RTX)
vs 29% (AZA)
p = 0.002
CYC = cyclophosphamide; GPA = granulomatosis with polyangiitis; i.v. = intravenous; MPA = microscopic polyangiitis; PDN = prednisone RL = renal limited; RTX =
rtituximab
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was reported in the RTX-treated and control arms. An im-
portant confounding factor is the concomitant use of CYC
in these studies, alongside the short follow-up periods. In
contrast, recent analysis of the long-term safety outcomes
of RTX in 370 patients from the German Registry of
Autoimmune Diseases, including 15.7% of which had
AAV, did not report any increased incidence of malignancy
across the entire study population [81]. Ten-year follow-up
of 108 AAV patients treated with RTX for remission in-
duction or maintenance reported infusion-related reactions
(7 patients; 6%) and infections (8 patients; 7%), but no
occurrence of malignancies [82]. Nevertheless, this point
deserves careful attention during long-term follow-up of
the RAVE and RITUXVAS data. Cumulative toxicity with
CYC bears a dose- and age-dependent risk of inducing in-
fertility and may induce premature menopause [83]. In con-
trast to CYC, RTX is not associated with infertility. Preg-
nancies under RTX treatment have been reported. A retro-
spective study analysed pregnancy outcome in women that
conceived whilst being treated with RTX. From 153 preg-
nancies in patients with various autoimmune and malignant
diseases treated with RTX with known outcomes, 90 res-
ulted in live births. Twenty-two infants were born prema-
turely; with one neonatal death at 6 weeks. Eleven neonates
had haematological abnormalities; none had corresponding
infections. Four neonatal infections were reported (fever,
bronchiolitis, cytomegalovirus hepatitis, and chorioamni-
onitis). Two congenital malformations were identified:
clubfoot in one twin, and cardiac malformation in a
singleton birth. These findings may have been confounded
by the concurrent use of other potentially teratogenic
agents [84].
In a more recent paper, five out of six pregnancies in pa-
tients with vasculitis treated with RTX were uneventful and
one early abortion occurred (in week 15). Of note, in all
of the three foetal cord blood samples tested, B cells were
present [85].
Owing to the potential risk for the newborn, contraception
after RTX treatment is mandatory and should be performed
according to existing guidelines.
Despite an apparently better toxicity profile, the rate of in-
fections at least during short term follow-up in the RAVE
and RITUXVAS trials in both the CYC- and RTX-treated
arms did not differ significantly [26, 30].
Conclusions
The approval of RTX not only provides a valuable altern-
ative treatment modality, but encourages us to rethink the
way in which we approach AAV. Today, the clinical chal-
lenge is shifting; in addition to reducing the disease bur-
den, a key goal is to minimise treatment-related damage.
RAVE, RITUXVAS and MAINRITSAN provide us with
an important vantage point from which to assess the po-
tential of RTX from a randomised, controlled perspective.
Overall, the currently available data suggest (a.) equival-
ence of RTX to CYC for induction treatment with poten-
tial superiority of RTX in relapsing disease (after induction
with CYC) and the potential to reduce some of the long
term adverse effects of CYC and (b.) possible superiority
of repeat RTX compared with azathioprine for maintenance
therapy. The main disadvantages of RTX are the consider-
ably higher price and the lack of very long-term data. When
balancing the risks and benefits of AAV treatment the fol-
lowing conclusions can be drawn from the discussed evid-
ence to aid in patient-tailored treatment decisions:
1. RTX is equivalent to CYC in inducing remission in
severe AAV.
2. RTX could be considered as the preferred regimen in
relapsing AAV (at least in RTX-naïve patients).
3. There is limited evidence for the use of RTX as
induction regimen in patients with creatinine >354
µmol/l or pulmonary haemorrhage requiring
mechanical ventilation at presentation. If RTX is used
in these patients, the addition of low dose CYC and/or
plasmapheresis should be considered.
4. RTX should be preferred over CYC in premenopausal
women whenever possible, because of the potential
induction of infertility (dose- and age-dependent in
women) [83].
5. The efficacy of RTX in localised and granulomatous
disease needs to be further studied.
6. RTX can be used as maintenance therapy as an
alternative to azathioprine or MTX. The best treatment
regimen will need to be defined as suggested strategies
vary widely.
7. Contraception is mandatory in fertile women after RTX
treatment owing to the lack of robust information on
the effect of RTX on newborns.
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